Nicolas Reyns

Dr. Nicolas Reyns


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2021 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
MVMaximilien Vermandel
Maximilien Vermandel
CDClément Dupont
Clément Dupont
FLFabienne Lecomte
Fabienne Lecomte
HLHenri-Arthur Leroy
Henri-Arthur Leroy
CTConstantin Tuleasca
Constantin Tuleasca
NRNicolas Reyns
Nicolas Reyns

1 July 2017 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
EREmilie Le Rhun
Emilie Le Rhun
DMDuhamel Marie
Duhamel Marie
Maxence WisztorskiMaxence Wisztorski
Maxence Wisztorski
JGJean-Pascal Gimeno
Jean-Pascal Gimeno
FZFahed Zairi
Fahed Zairi
IFIsabelle Fournier
Isabelle Fournier

17 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Henri-Arthur LeroyHenri-Arthur Leroy
Henri-Arthur Leroy
GBGrégory BAERT
Grégory BAERT
LGLaura Guerin
Laura Guerin
Nadira DelhemNadira Delhem
Nadira Delhem
Serge MordonSerge Mordon
Serge Mordon
AVAnne-Sophie VIGNION-DEWALLE
Anne-Sophie VIGNION-DEWALLE
Glioblastomas (GBMs) are high-grade malignancies with a poor prognosis. The current standard of care for GBM is maximal surgical resection followed by radiotherapy and chemotherapy. Despite all these treatments, the overall survival is still limited, with a median of 15 months. For patients harboring inoperable GBM, due to the anatomical location of the tumor or poor general condition of the patient, the life expectancy is even worse. The challenge of managing GBM is therefore to improve the local control especially for non-surgical patients. Interstitial photodynamic therapy (iPDT) is a minimally invasive treatment relying on the interaction of light, a photosensitizer and oxygen. In the case of brain tumors, iPDT consists of introducing one or several optical fibers in the tumor area, without large craniotomy, to illuminate the photosensitized tumor cells. It induces necrosis and/or apoptosis of the tumor cells, and it can destruct the tumor vasculature and produces an acute inflammatory response that attracts leukocytes. Interstitial PDT has already been applied in the treatment of brain tumors with very promising results. However, no standardized procedure has emerged from previous studies. Herein, we propose a standardized and reproducible workflow for the clinical application of iPDT to GBM. This workflow, which involves intraoperative imaging, a dedicated treatment planning system (TPS) and robotic assistance for the implantation of stereotactic optical fibers, represents a key step in the deployment of iPDT for the treatment of GBM. This end-to-end procedure has been validated on a phantom in real operating room conditions. The thorough description of a fully integrated iPDT workflow is an essential step forward to a clinical trial to evaluate iPDT in the treatment of GBM.

16 May 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
IPIulia Peciu-Florianu
Iulia Peciu-Florianu
QVQuentin Vannod-Michel
Quentin Vannod-Michel
EVEnora Vauleon
Enora Vauleon
MBMarie-Edith Bonneterre
Marie-Edith Bonneterre
NRNicolas Reyns
Nicolas Reyns
Purpose: Glioblastoma remains incurable despite optimal multimodal management. The interim analysis of open label, single arm INDYGO pilot trial showed actuarial 12-months progression-free survival (PFS) of 60% (median 17.1 months), actuarial 12-months overall survival (OS) of 80% (median 23.1 months). We report updated, exploratory analyses of OS, PFS, and health-related quality of life (HRQOL) for patients receiving intraoperative photodynamic therapy (PDT) with 5-aminolevulinic acid hydrochloride (5-ALA HCl). Methods: Ten patients were included (May 2017 – April 2021) for standardized therapeutic approach including 5-ALA HCl fluorescence-guided surgery (FGS), followed by intraoperative PDT with a single 200 J/cm2 dose of light. Postoperatively, patients received adjuvant therapy (Stupp protocol) then followed every 3 months (clinical and cerebral MRI) and until disease progression and/or death. Procedure safety and toxicity occurring during the first four weeks after PDT were assessed. Data concerning relapse, HRQOL and survival were prospectively collected and analyzed. Results: At the cut-off date (i.e., November 1st 2023), median follow-up was 23 months (9,7–71,4). No unacceptable or unexpected toxicities and no treatment-related deaths occurred during the study. Kaplan–Meier estimated 23.4 months median OS, actuarial 12-month PFS rate 60%, actuarial 12-month, 24-month, and 5-year OS rates 80%, 50% and 40%, respectively. Four patients were still alive (1 patient free of recurrence). Conclusion: At 5 years-follow-up, intraoperative PDT with surgical maximal excision as initial therapy and standard adjuvant treatment suggests an increase of time to recurrence and overall survival in a high proportion of patients. Quality of life was maintained without any severe side effects. Trial registration NCT number: NCT03048240. EudraCT number: 2016–002706-39.

1 June 2017 in Neurochirurgie
Verified
Journal Article
Closed access
NRNicolas Reyns
Nicolas Reyns
HLH.-A. Leroy
H.-A. Leroy
CDC. Delmaire
C. Delmaire
BDB. Derre
B. Derre
ELE. Le-Rhun
E. Le-Rhun
JLJ.-P. Lejeune
J.-P. Lejeune

6 February 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
XLX. Leclerc
X. Leclerc
OGO. Guillaud
O. Guillaud
NRNicolas Reyns
Nicolas Reyns
JHJ. Hodel
J. Hodel
OOO. Outteryck
O. Outteryck
GKG. Kuchcinski
G. Kuchcinski
BACKGROUND AND PURPOSE: Follow-up MR imaging of brain AVMs currently relies on contrast-enhanced sequences. Noncontrast techniques, including arterial spin-labeling and TOF, may have value in detecting a residual nidus after radiosurgery. The aim of this study was to compare noncontrast with contrast-enhanced MR imaging for the differentiation of residual-versus-obliterated brain AVMs in radiosurgically treated patients. MATERIALS AND METHODS: Twenty-eight consecutive patients with small brain AVMs (<20 mm) treated by radiosurgery were followed with the same MR imaging protocol. Three neuroradiologists, blinded to the results, independently reviewed the following: 1) postcontrast images alone (4D contrast-enhanced MRA and postcontrast 3D T1 gradient recalled-echo), 2) arterial spin-labeling and TOF images alone, and 3) all MR images combined. The primary end point was the detection of residual brain AVMs using a 5-point scale, with DSA as the reference standard. RESULTS: The highest interobserver agreement was for arterial spin-labeling/TOF (κ = 0.81; 95% confidence interval, 0.66–0.93). Regarding brain AVM detection, arterial spin-labeling/TOF had higher sensitivity (sensitivity, 85%; specificity, 100%; 95% CI, 62–97) than contrast-enhanced MR imaging (sensitivity, 55%; specificity, 100%; 95% CI, 27–73) and all MR images combined (sensitivity, 75%; specificity, 100%; 95% CI, 51–91) (P = .008). All nidus obliterations on DSA were detected on MR imaging. In 6 patients, a residual brain AVM present on DSA was only detected with arterial spin-labeling/TOF, including 3 based solely on arterial spin-labeling images. CONCLUSIONS: In this study of radiosurgically treated patients with small brain AVMs, arterial spin-labeling/TOF was found to be superior to gadolinium-enhanced MR imaging in detecting residual AVMs.